進化するがん免疫療法、今秋にもGL改訂臨床腫瘍学会、臓器横断の新たな適応も

( エーブィエ バイオファーム)2018/7/18 04:30日本臨床腫瘍学会は今秋に、「がん免疫療法ガイドライン（GL）」を改訂する方針だ。2016年12月に刊行されたばかりだが、免疫チェックポイント（CP）阻害剤をはじめとするがん免疫療法が日々進化している...

中外、エントレクチニブを導入ロシュのROS1/TRK阻害剤

 ( エーブィエ バイオファーム)2018/7/17中外製薬は17日、ROS1/TRK阻害剤エントレクチニブについて、スイス・ロシュと導入契約を締結したと発表した。同剤はROS1融合遺伝子陽性の非小細胞肺がん、およびNTRK融合遺伝子陽性の固形がん...

(中研院) 果蠅大腦 隱藏 自閉症/精神分裂症/帕金森氏症 解藥!

"基因篩選平台" 有望阻帕金森氏症惡化 2018-7-17醫藥新聞自閉症、帕金森氏症等精神疾病，可望獲得控制嗎？中研院研究團隊，利用果蠅大腦，研發出一套基因篩選工具，可以標定出細胞中有保護機制的訊息分子，因為果蠅大腦中的神經細胞跟人類相似，因此未來只要找出可以啟動細胞保護機制的藥物，可望就能阻止疾病惡化或病變。顯微鏡下解剖果蠅大腦中研院研究團隊耗費7年從果蠅大腦中的神經細胞建立出一套基因篩選平台將有助於治療像是帕金森氏症等神經退化疾病團隊利用篩選平台從成蠅大腦裡嗅覺區域的中介神經元中找出工具可以標定出有保護機制的訊息分子未來只要利用藥物就可能啟動保護機制阻斷死亡細胞擴散有望阻止像是自閉症、精神分裂症或帕金森氏症等精神疾病病情惡化或病變研究成果還登上國際學術期刊未來團隊將利用果蠅大腦研究找出人腦神經系統的差異性朝精準醫學發展讓疾病更能對症下藥

晟德CS02特殊機轉 穩定血糖&HbA1c: Lower level of Ca+2 , the lower level of TXNIP (thioredoxin-interacting protein)

晟德與華潤醫藥簽署糖尿病新藥CS02大陸獨家授權MOU MoneyDJ新聞 2018-07-16記者 新聞中心 報導晟德(4123)上周五(13日)宣布與中國華潤醫藥集團有限公司(3320.HK)旗下之華潤醫藥控股公司簽署糖尿病新藥CS02獨家授權大陸市場的開發與商業化合作備忘錄案(MOU)，其中的簽約金加上里程碑金為8000萬元人民幣，而銷售權利金最高可達兩位數的百分比；同時，華潤醫藥控股將負責實施與管理大陸市場的臨床研究工作、負擔CS02在當地的臨床研究費用與藥品註冊相關費用，並於獲得中國國家食品藥品監督管理總局(CFDA)批准上市後，負責CS02在大陸的商業化推廣。晟德大藥廠總經理許瑞寶表示，晟德大藥廠除持續專注於優化水劑產品組合，也相當重視研發實力的養成，在特殊藥物項目開發上更是不遺餘力。華潤醫藥控股為大陸領先的綜合醫藥公司，深耕醫療及保健產品領域並擁有豐富的藥品開發資源及完善的銷售通路體系；晟德很高興能與華潤醫藥控股合作，雙方互補共利並齊心加速CS02在大陸市場的上市時程，早日嘉惠更多病患。晟德並指出，根據國際糖尿病聯盟(IDF)於去(2017)年發表之全球糖尿病地圖(IDF Diabetes Atlas)報告，去年全球約有4.25億糖尿病人口，同年因糖尿病死亡的人數約為400萬。IDF同時預測至2045年全球罹患糖尿病的人口將高達6.29億；此外，中國糖尿病人口已躍居全球之冠，糖尿病患病率為10.9%，約達1.14億並持續快速成長中。晟德並指出，其創新機轉糖尿病候選新藥CS02已於台美兩地針對第二型糖尿病病人進行二期人體臨床試驗，預計於明(2019)年底至2020上半年完成收案。根據多次動物實驗結果顯示，CS02的特殊機轉能有效降低並穩定小鼠血糖以及糖化血色素(HbA1c)；此外，已有文獻證實CS02相關成份具有恢復受損胰島beta細胞的潛力，相對於現行藥物大多僅聚焦於控制血糖的功能，CS02可望從根本改善糖尿病問題，成為糖尿病病友新佳音。

Potential Mechanism of Action: Consolidated the potential MoA of CS02 in diabetes treatment : In beta cells, the higher level of Ca+2, the higher level of TXNIP (thioredoxin-interacting protein), and this will lead to beta cell apoptosis ; the lower level of Ca+2 , the lower level of TXNIP, and this will prevent beta cell from apoptosis.

糖尿病治疗药物GLP-1 medication恶心呕吐解药: vitamin B-12 !!!

Common type 2 diabetes drug could be mixed with vitamin B to stop medication causing nausea and vomiting, finds study By SAM BLANCHARD FOR MAILONLINEPUBLISHED: 18:10 BST, 17 July 2018 | UPDATED: 21:30 BST, 17 July 2018 People with Type 2 diabetes cannot properly regulate the levels of sugar in their blood because their body does not use the hormone insulin normally. GLP-1 medications mimic the hormones in a non-diabetic person's body to prevent patients' blood sugar getting too high. Up to 50 per cent of people on medication get nausea They are widely prescribed but cause nausea and vomiting in as many as half of people who take them. The condition means the body does not react properly to insulin – the hormone which controls absorption of sugar into the blood – and cannot properly regulate blood glucose levels. Excess fat in the liver increases the risk of developing type 2 diabetes as the buildup makes it harder to control glucose levels, and also makes the body more resistant to insulin. This, the researchers say, is a reason many people stop taking medications, which can increase their risk of deadly complications from the condition. 'Drug regimens often have long lists of side effects which negatively impact treatment,' said Bart De  Jonghe of University of Pennsylvania School. Side effects stop people from taking their medicine' In Type 2 diabetes, nausea and vomiting top that list. It's the main reason people stop taking their diabetes medications, and diminishes quality of life for millions who do take them. 'In the study the scientists found attaching vitamin B-12 stopped the drug triggering the part of the brain which causes vomiting. Some 90 per cent of shrews which took the unmodified drug were sick, but only 12 per cent of those that were given the vitamin-combined drug vomited. Shrews were used for the study because mice and lab rats are unable to throw up. Dr De Jonghe added: 'The vomiting results are striking and very encouraging. 'It's rare to see such positive results with a new drug compared to the standard. It's hard to not be optimistic.' Type 2 diabetes is closely associated with obesity and other risk factors include genetics, being over 40 years old, or being of of south Asian, Chinese, African Caribbean or black African origin.